# China Updates Its Medical Device Adverse Event Report Form

China's National Center for Adverse Drug Reaction Monitoring published its [2026 revision of the Medical Device Adverse Event Report Form](https://www.cdr-adr.org.cn/tzgg_home/202611/t20261117_51835.html) on **17 November 2026** after approval by the National Medical Products Administration (NMPA). The center published the [revised form](https://www.cdr-adr.org.cn/tzgg_home/202611/W020261117501632878391.docx) and an [official Q&A](https://www.cdr-adr.org.cn/tzgg_home/202611/W020261117416019216006.docx). The Q&A ties the switchover to the launch of the upgraded monitoring system and gives no calendar date. A filling guide and further FAQs will follow after the form goes into use.

## What changes in the upgraded portal

The center is combining two forms into one. The portal will show different fields to registrants and filing holders, distributors, healthcare institutions and individual reporters. For example, the form lists software and firmware version fields for active devices, with firmware shown only to registrants, filing holders and agents (rows 27 and 28). For implantable devices, it calculates implant duration from the implantation and removal dates. When either date is incomplete, reporters enter the duration (rows 30–32).

For registrants, filing holders and their China agents, the new form makes searchable International Medical Device Regulators Forum (IMDRF) terminology part of several reporting decisions.

| What the reporter is documenting | What the form calls for |
| --- | --- |
| Injury | Rows 41 and 42 require injury manifestation and health impact when injury is selected. Registrants, filing holders and agents use IMDRF Annex E and F terms. |
| Product problem or implicated component | Row 44 is required when the event is classified as a product problem without injury. Registrants, filing holders and agents use Annex A terms for the product problem and Annex G terms for the component in row 45. |
| Investigation | Rows 71–73 accept structured terms for investigation type, findings and conclusion. The form includes options for findings and conclusions that are still pending. Row 74 accepts narrative text and attachments. |

Other reporters can use free text in rows 41, 42, 44 and 45. The form allows standardized terms to be added during evaluation when, for example, a healthcare institution supplied free text or entered an inaccurate term.

## Preliminary and final evaluations

When a registrant or filing holder submits an evaluation, the portal will ask whether further updates are needed (rows 13 and 14). If so, the case moves to initial evaluation and the first evaluation must record preliminary control measures (row 77). A final evaluation or a report that needs no further update calls for final control measures (row 78). Both fields ask whether selected changes to design, manufacturing, software, or labeling and instructions for use require a registration or filing change.

The Q&A says the portal will retrieve existing device information from a registration or filing number or unique device identifier. It will block submission when required information is missing, codes fail format checks or dates conflict. It also says the captured data can be reused in periodic risk evaluation reports and in periodic safety update reports under the device vigilance pilot.

## How to prepare before the switchover

**Pure Global analysis.** Test your intake process against two representative cases before changing your reporting workflow. For a hospital-originated injury, check that your local agent can map the hospital's description to the Annex E and F fields. For a device problem that requires a follow-up, check that your file can carry an open investigation, preliminary measures and a later final evaluation. For active or implantable products, confirm your intake captures the version or implant-history data the form displays for those devices.

[Canonical page](https://www.pureglobal.com/news/china-nmpa-cdr-medical-device-adverse-event-report-form-2026)
